Ciguatera, the most common form of nonbacterial ichthyosarcotoxism, is caused by consumption of fish that have bioaccumulated the polyether sodium channel activator ciguatoxin. The neurological symptoms of ciguatera include distressing, often persistent sensory disturbances such as paraesthesias and the pathognomonic symptom of cold allodynia. We show that intracutaneous administration of ciguatoxin in humans elicits a pronounced axon-reflex flare and replicates cold allodynia. To identify compounds able to inhibit ciguatoxin-induced Na v responses, we developed a novel in vitro ciguatoxin assay using the human neuroblastoma cell line SH-SY5Y. Pharmacological characterisation of this assay demonstrated a major contribution of Na v 1.2 and Na v 1.3, but not Na v 1.7, to ciguatoxin-induced Ca 2+ responses. Clinically available Na v inhibitors, as well as the K v 7 agonist flupirtine, inhibited tetrodotoxin-sensitive ciguatoxin-evoked responses. To establish their in vivo efficacy, we used a novel animal model of ciguatoxin-induced cold allodynia. However, differences in the efficacy of these compounds to reverse ciguatoxin-induced cold allodynia did not correlate with their potency to inhibit ciguatoxininduced responses in SH-SY5Y cells or at heterologously expressed Na v 1.3, Na v 1.6, Na v 1.7, or Na v 1.8, indicating cold allodynia might be more complex than simple activation of Na v channels. These findings highlight the need for suitable animal models to guide the empiric choice of analgesics, and suggest that lamotrigine and flupirtine could be potentially useful for the treatment of ciguatera. Ó
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Introduction
Ciguatera is a perplexing neurological disease caused by consumption of highly lipophilic polyether compounds known as ciguatoxins (CTX) that bioaccumulate in tropical and subtropical fish. Clinically, ciguatera is associated with gastrointestinal disturbances of limited duration, in particular nausea, diarrhoea, and abdominal pain, with neurological disturbances being the predominant presentation. The neurological symptoms of ciguatera include distressing, often persistent sensory disturbances such as perioral and distal paraesthesias, dysesthesias, pruritus, headache, and asthenia [18, 21] . Of these neurological disturbances, temperature dysesthesia, or cold allodynia, is considered pathognomonic and occurs in up to 95% of those with ciguatera [3, 21] .
At the molecular level, ciguatoxin is the most potent known activator of voltage-gated sodium channels (Na v ) [23] . Ciguatoxin also inhibits neuronal potassium channels [5] , resulting in further increased neuronal excitability. The pharmacological action of ciguatoxins on Na v in excitable cells results in a range of pathophysiological effects, including spontaneous action potential discharge, release of neurotransmitters, increase of intracellular Ca
2+
, and axonal Schwann cell oedema (for review, see [27] ). Importantly, clinical management of the peripheral sensory disturbances associated with ciguatera, in particular cold allodynia, remains symptomatic and relies on the largely empiric choice of analgesics. This reflects both difficulties in recruiting ciguatera patients in sufficient numbers for systematic randomised controlled trials, as well as the absence of suitable in vitro and in vivo models able to assess the therapeutic potential of various compounds. We thus sought to establish a novel in vitro ciguatoxin assay to identify inhibitors of acute ciguatoxin-induced Na v activation at the cellular level. In addition, we systematically evaluated the antiallodynic effects of approved analgesic drugs and medications modulating neuronal excitability in a novel animal model
